True, I've seen a mixture of numbers reported, but I believe it is important to compare between cell lines. With what I think is considered an authoritative line, that is the Calu-3 cell line, Brilacidin is not only less cytotoxic, but also a more effective antiviral.
Thank you both for this. My question still stands even though we're looking at these numbers.
We know B is highly effective at killing the virus and we know that it has very low toxicity.
We aren't worried about cytotoxicity with Brilacidin. We're worried about whether the safe dosages we have established (0.6×3 days) is enough to generate enough antiviral activity to give a successful result.
Even if our SI was 100 or 600 or 1000 we still are capped at the same dosage to avoid the SAEs seen in the Polymedix trial, right?
So high SI is good when your dosage is limited by cytotoxicity. It doesnt seem as meaningful when our drug is limited by systemic SAEs.
News 
Market Data 
Discover 
